FOLH1 and prostate carcinoma: A number of antibody alternative reagents targeting prostate-specific membrane antigen (PSMA), a prostate cancer biomarker, have been developed (Chatalic et al. 2015; Han et al. 2016, Mazzocco et al. 2016).